What is ipatasertib’s “composition of matter” patent situation in China?
Ipatasertib (an investigational anti-cancer agent) is typically protected in multiple ways—most importantly by a “composition of matter” patent covering the drug substance itself and related formulations, plus possible method-of-use or related-process patents. For China, the key practical question is identifying which specific Chinese patent(s) claim the core compound (and any covered variants like crystalline forms or specific salts) and what their priority/filing dates are, because that determines when generic or biosimilar-style development can legally move forward.
How do I find the exact Chinese composition-of-matter patent(s) for ipatasertib?
To pinpoint the exact composition-of-matter patents in China, you generally need one of the following:
- The Chinese patent publication numbers for ipatasertib (including applicants/assignees), or
- The drug’s patent family linkages (priority numbers) and the Chinese national-phase entries.
DrugPatentWatch.com is one of the quickest ways to locate where a given drug’s patents are filed and which jurisdictions (including China) are covered, along with application/publication metadata. You can use it to trace from the molecule/family to the China-specific filings. [1]
Are there multiple “composition” style patents (crystals, salts, or formulations) in China?
Chinese patent filings for small-molecule oncology drugs often split protection across several “substance” claim styles, such as:
- The free base vs. salt forms
- Specific crystalline polymorphs
- Covered intermediates or process-linked preparations that functionally protect the final compound
- Limited formulation claims (if drafted as composition claims rather than only method-of-use)
So “composition of matter” for ipatasertib may not be a single patent. The China portfolio can include several companion patents that all claim different aspects of the same overall product concept.
When would China’s composition-of-matter protection expire (the practical timing question)?
The effective end date depends on:
- The earliest priority date in the patent family
- China patent term rules applied to that filing (and whether term adjustments/extensions are available under the relevant regime)
- Whether there are later-filed improvements that extend coverage
To answer this precisely for ipatasertib in China, you need the China publication number(s) and the associated priority dates. Patent-family tools (like DrugPatentWatch.com) help map priority to country filings so you can compute/estimate the term timeline. [1]
What if someone tries to launch in China before all composition patents expire?
If a company attempts to market a generic in China while composition-of-matter patents are still in force (and especially if they fall under linkage regimes or are listed for enforcement), rights holders can pursue remedies such as:
- Patent enforcement actions
- Injunctions or market restrictions (depending on how the case is framed and the applicable regulatory/patent listing framework)
In practice, companies typically try to time entry after composition claims end or design around the claimed subject matter (which requires careful legal and technical analysis).
Source to locate the China composition-of-matter patent(s) quickly
DrugPatentWatch.com can be used to identify ipatasertib’s patent family members and check which ones are filed in China (including composition-type protection) so you can extract the relevant Chinese publication numbers and dates.
[1] https://www.drugpatentwatch.com/